Posted: 27 July 2024
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to share the power of the geneType test in identifying risk and improving the health of populations worldwide.
Since the geneType Risk Assessment Tests became available, GTG has tested a statistically significant number of people in Australia and the US. These results have revealed a compelling statistic: 79.5% of individuals tested* 0F 1showed an elevated risk for at least one disease. GTG believes this is a significant finding driving increased surveillance and screening which will ultimately lead to early detection, early intervention and, ultimately, save lives.
GeneType is revolutionizing healthcare with its pioneering, non-invasive Multi-Risk Test, designed to uncover hidden risks of common yet serious diseases. This state-of-the-art test identifies individuals at elevated risk for a range of cancers, including breast, ovarian, pancreatic, prostate, colorectal, and melanoma, as well as cardiovascular diseases and metabolic conditions like Type 2 diabetes.
Why GeneType’s Multi-Risk Test is a Game-Changer:
- Comprehensive Coverage: The Multi-Risk Test evaluates genetic predispositions across a spectrum of serious diseases, covering 70% of annual mortality and morbidities – providing a clearer view of an individual’s health risks.
- Non-Invasive Procedure: The geneType test uses a simple, non-invasive salvia sample, making it accessible to a much wider population than a blood sample.
- Actionable Outcomes: Each test in geneType’s portfolio comes with guideline-driven, actionable outcomes, empowering patients and healthcare providers to make informed decisions.
- Early Detection Saves Lives: Identifying individuals at high risk enables proactive monitoring and preventative measures, significantly improving health outcomes.
- Personalised Care: This test epitomises the power of genomics and personalised care, tailoring health management to the individual.
Real Impact, Real Lives:
The implications of geneType’s Multi-Risk Test are profound. With 80% of tested individuals discovering an elevated risk for serious diseases, the need for proactive health management has never been clearer. This test not only identifies hidden risks but also initiates a shift towards a more preventative approach in healthcare, enhancing the chances of early intervention and treatment.
“We have always believed the geneType Multi-Risk Test is a major step forward in personalised medicine,” said Simon Morriss, CEO of geneType. “These real time results validate the utility of geneType in identifying people at high risk of disease, and importantly, they enable individuals and healthcare providers to take control of their health.”
